Analysis of the efficacy of anlotinib on lung metastasis of osteosarcoma
Objective To analyze the efficacy of anlotinib for patients with osteosarcoma lung metastasis.Methods A retrospective analysis was performed on 28 patients with osteosarcoma admitted to our hospital from January 2018 to November 2022.All had lung metastasis and were treated with anlotinib.The median age of patients was 21 years(range:7-62 years),including 19 males and 9 females.Patients had at least one 5 mm nodular lesion in the lungs.All patients took the drug for 3 weeks as a cycle(2 weeks of drug,1 week of discontinuation),and took the drug for at least 3 cycles or more.In addition to 5 patients with anlotinib alone,anlotinib was treated in combination with chemotherapy,radiotherapy,immunotherapy or surgery.Results Follow-up lasted 4-50 months.The median follow-up time was 15 months.There were 17 deaths and 11 survivors,and the overall survival rate was 42.86%.82.14%(23/28)of patients had progression of lung lesions,and only 5 cases had no progression of lung lesions.The median progression-free survival(m-PFS)of all cases was 7.17 months and the median overall survival(m-OS)was 15.00 months.After analysis,it was found the patients who had the larger the volume of lung lesions,or extrapulmonary metastases,or previous use of targeted drug had the worse treatment effect and the worse prognosis.Combination therapy,time of occurrence of lung lesions,and the number of lung lesions were not significantly correlated with the efficacy.Among all patients,19(67.86%)patients had 22 complications of varying degrees,of which grade 1/2 complications accounted for 86.36%of all complications.Conclusions Anlotinib has a positive effect on patients with osteosarcoma lung metastases,and early combination can be considered.There is insufficient evidence for efficacy with monotherapy.Complications are generally tolerated.
NETL
NSTL
万方数据
